CD274 and neoplasm: A recent study conducted in a TC1 mouse tumor model showed that the combination of Lm-LLO-E7 with an anti–PD-1 antibody that blocks the PD-1/PD-L1 interaction significantly improved the immunotherapeutic efficacy of treatment compared with Lm-LLO-E7 alone [40].